Not medical advice. Talk to your provider before using any peptide.
Full disclaimerPeptide Schedule Research TeamReviewed Apr 20267 Citations
Cagrilintide activates amylin receptors, a pathway GLP-1 drugs miss entirely. REDEFINE 1 confirmed 11.5% weight loss as monotherapy and 20.4% combined with semaglutide at 68 weeks. CagriSema NDA is under FDA review. All standalone supply remains research-grade with no regulatory oversight.
250mcg · Weekly
Summary: Add 2mL BAC water to your 5mg vial. Draw to 10.0 units on a U-100 syringe for a 250mcg dose. This vial will last 20 doses.
View side effects and safety warnings →
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 250mcg | Weekly |
| Moderate | 1mg | Weekly |
| Aggressive | 2,400mcg | Weekly |
Most common mistake: starting at 0.5 mg instead of 0.25 mg. The seven-day half-life means each dose stacks on the previous one during accumulation. Starting at double the validated initiation dose makes the first month of GI effects far worse than necessary. Reconstitution math for a 5 mg vial: add 2 mL bacteriostatic water. That gives you 2,500 mcg per mL. On a U-100 insulin syringe, each IU mark equals 25 mcg. So 0.25 mg (250 mcg) is 10 IU; 0.5 mg is 20 IU; 1.0 mg is 40 IU; 1.7 mg is 68 IU; 2.4 mg is 96 IU. One 5 mg vial covers roughly the first two titration steps (about 3 mg total across 8 weeks). Use bacteriostatic water, not acetic acid. Amylin peptides form fibrils at low pH. If the reconstituted solution looks cloudy or shows particles, discard the vial. Refrigerate at 2 to 8 degrees C, protect from light and agitation, use within 4 weeks. If you're also running semaglutide, inject at separate anatomical sites. Separate days let you isolate which peptide is causing any GI issues.
Dosing based on REDEFINE 1 Phase 3 Trial: cagrilintide vs placebo (NEJM 2025) — 11 published references.View all sources →
Cross-check your Cagrilintide reconstitution math with AI
Pricing updated 2026-04-09
Prices are estimates and vary by source, location, and prescription status.Full pricing breakdown →
Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
Cagrilintide activates amylin receptors, a pathway GLP-1 drugs miss entirely. REDEFINE 1 confirmed 11.5% weight loss as monotherapy and 20.4% combined with semaglutide at 68 weeks. CagriSema NDA is under FDA review. All standalone supply remains research-grade with no regulatory oversight.